Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
Sponsor: Kilimanjaro Christian Medical Centre, Tanzania
This PHASE2 trial investigates Cardiac Safety and Cardiotoxicity and is currently completed. Kilimanjaro Christian Medical Centre, Tanzania leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jul 2018 — Jan 2020 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kilimanjaro Christian Medical Centre, Tanzania
- London School of Hygiene and Tropical Medicine
- National Institute for Medical Research, Tanzania
For direct contact, visit the study record on ClinicalTrials.gov .